Search PubMed⌕ Search

Biomedical subjects

B Lange

Publications and source records attributed to B Lange.

At least 145 records · Page 8Linked to original sources
PubMed1983

[Spectral analysis of rapid (beta) EEG activity].

Spectral analysis techniques provide high resolution of the beta frequency range and, if a logarithmic transformation is used, also of lower level intensity. This is in contrast to the generally poor resolution of fast activity in the time domain, an effect which may be compared with that of a magnifying glass applied to beta activity. In the frequency domain several different types of beta activity may be distinguished, i.e., (1) narrow; (2) medium; (3) broad-band beta; (4) harmonic beta where the beta component shows a harmonic relationship to a lower frequency component; (5) complex beta as a mixture of 2 or more of the foregoing types; and (6) undefined beta, where the relative increase of beta power is the only assessable feature. If observed, significant coherence occurs most frequently between antero-posterior leads in activities of types 1 and 2, whereas coherence between hemispheres is generally low. Broad-band beta seems to be essentially non-coherent. Coherence of harmonic beta depends largely on the features of the underlying component. Bi-coherence analysis may be of help to further analysis of harmonic or complex beta activity.

Beta Rhythm↗
PubMed1983

Antigenically distinct subpopulations of myeloid progenitor cells (CFU-GM) in human peripheral blood and marrow.

Two types of progenitor cells of the human granulocytic and monocytic lineages (CFU-GM) can be distinguished by using mouse monoclonal antibodies against human hemopoietic cells. Type 1 CFU-GM contribute all of the peripheral blood CFU-GM as well as a small fraction of bone marrow CFU-GM and express surface antigens recognized by "anti-lymphomonocytic" monoclonal antibodies S3-13 and S17-25 but not the antigens recognized by R1B19 and WGHS-29-1 (two monoclonal antibodies that react with all the cells of the granulocytic lineage). Type 2 CFU-GM are present only in the marrow and react with S3-13, R1B19, and WGHS-29-1. Partial reactivity with S17-25 was observed only in the complement-dependent cytotoxicity test. In vitro culture of type 1 CFU-GM in liquid medium in the presence of granulocyte-macrophage colony-stimulatory factor (GM-CSF) generates colony-forming cells that have the surface phenotype of type 2 CFU-GM. This finding supports the idea of two different stages of maturation of myelomonocytic progenitor cells represented by type 1 and type 2 CFU-GM.

Adult↗
PubMed1983

Spectral analysis of all-night sleep EEG in healthy adults.

Power and coherence spectra were computed from all-night sleep EEG records in 6 healthy adult subjects. Derivations were from F3, F4, P3, P4, O1, O2, T3, and T4 to the vertex (Cz). Records were conventionally scored into sleep stages. Average power per sleep stage was maximal at frequencies 0.4-6 c/s in stage 4, at 6-10 c/s in either stage 3 or stage 4, at 12-14 c/s in stage 2 and at 14-30 c/s in stage 1. The average power range from highest values in the lowest frequency band to lowest values in the highest frequency band showed marked differences between sleep stages: It was lowest (12-14 dB) in stage 1, followed by stage 2 (20-22 dB), and stage 3 (16-28 dB), and largest in stage 4 (29-32 dB). REM sleep (15-16 sB) was between stage 1 and 2. The waking state showed an average power range of 11-15 dB. Alpha power at 8-10 c/s in occipital and parietal leads was remarkably constant during sleep, i.e. independent of sleep stage. Coherence showed maximal values at 2-8 c/s in REM sleep, at 8-12 c/s in stage 4, at 12-17 c/s in either stage 3 or 4, and at 17-30 c/s again in stage REM. There was significant coherence increase at 2-8 and 17-30 c/s from NREM to REM sleep, most pronounced between parietal to vertex derivations. Overall coherence between both occipital-to-vertex, or between occipital and parietal-to-vertex derivations, was essentially higher than in the other derivations. The results, essentially, give a comprehensive phenomenology of the dynamic spectral structure of all-night sleep EEG. They suggest that the different brain states during sleep (e.g. stage 1 NREM vs. REM) which are associated with different functions (e.g. hypnagogic hallucinations vs. dreams) differ in EEG spectral parameters if coherence is considered. Likewise, they suggest that studies of automatic sleep staging based exclusively on EEG spectral parameters appear promising.

Adult↗
PubMed1983

Differentiation antigens of human hemopoietic cells: patterns of reactivity of two monoclonal antibodies.

Two mouse anti-human monoclonal antibodies (S3.13 and S5.7) raised against cells of acute myelogenous leukemia were found to react with antigens expressed on the surface of subsets of monocytes and lymphocytes. S3.13 precipitates a peptide of Mr 29,000, and S5.7 precipitates a peptide of Mr 20,000 present on the surface of all the cell types tested. These two surface antigens were distributed on discrete subpopulations of normal hemopoietic cells. The antibodies reacted with all (S5.7) or a subpopulation (S3.13) of peripheral blood T-lymphocytes, and with a subset of monocytes. Both antibodies reacted with bone marrow blast cell progenitors of the myelomonocytes and erythroid lineage. S5.7 also reacted with non-T-lymphocytes and with cells of the eosinophilic lineage. Both antigens disappeared from the cell surface during normal myeloid and erythroid differentiation. Thus, these monoclonal antibodies define the molecular characteristics and the cellular distribution of two differentiation antigens present on cells of the hemopoietic lineage.

Animals↗
PubMed1982

Increase in numbers of 6-thioguanine-resistant human lymphocytes in short-term culture.

Lymphocytes from healthy young adults and from adolescent patients with cancer were examined for their ability to incorporate [3H]thymidine in short-term culture in the presence of phytohemagglutinin and 6-thioguanine (6-TG). The numbers of labeled nuclei after 72 h in culture were compared to numbers of labeled nuclei after 30 h in culture. The numbers of labeled nuclei in the presence of 6-TG increased 6-65-fold between 30 and 72 h. The increases in number could be accounted for by 3-6 cycles of cell division. The data suggest that 6-TG-resistant peripheral blood lymphocytes are capable of reproduction in short-term culture, but factors other than reproduction may also contribute to increases in numbers of 6-TG-resistant cells.

Adult↗
PubMed1982

High-dose methotrexate and adriamycin in osteogenic sarcoma: the children's hospital of Philadelphia study.

From 1975 through 1979, 25 patients with osteosarcoma received therapy with vincristine, high-dose methotrexate, citrovorum factor, and Adriamycin. Five patients had metastases prior to receiving chemotherapy, and 11 of the remaining 20 nonmetastatic patients received preoperative or preirradiation chemotherapy. Chemotherapy caused objective tumor regression in 1 of 5 patients with metastases and 1 of 11 with measurable primaries. All five patients with metastatic disease died 7-16 months from diagnosis. Of the 20 nonmetastatic patients, 4 did not have primary amputations: all died. Of 16 patients with primary amputations, 6 are alive relapse-free 24-86 months from diagnosis, and 10 are dead. The actuarial survival of 36% is not statistically different from that of historical control groups or from that of concurrent control groups treated with surgery alone. However, because most adjuvant chemotherapy studies have involved few patients, 36% survival is not statistically different from the 50-70+% survival reported in previous studies. Our data fail to demonstrate that the adjuvant chemotherapy has improved the survival rate of children with osteosarcoma. We support a randomized, controlled comparison of adjuvant chemotherapy and aggressive surgical resection.

Actuarial Analysis↗
PubMed1982

Monoclonal antibodies that detect differentiation surface antigens on human myelomonocytic cells.

We describe here the production and characterization of several new monoclonal antibodies that recognize differentiation antigens present on human cells of the myelomonocytic lineage. The lineage and the stage specificities of our reagents (myeloid-, monocytic-, and myelomonocytic-specific) were determined on the basis of their reactivity with human cell lines and with human peripheral blood and bone marrow cells. Cross-competition experiments demonstrated that some of the antibodies react with the same or closely associated antigenic determinants. Five antigens have been identified in this way: one present on myeloid, one on monocytic, and three on both myeloid and monocytic cells. The possible relationship of our antibodies with other established monoclonal antibodies is discussed, in addition to their use in the in vitro study of the differentiation pathways of human hemopoietic cells and in the characterization of leukemias.

Animals↗
PubMed1982

A monoclonal antibody that detects expression of transferrin receptor in human erythroid precursor cells.

A monoclonal antibody, L5.1, obtained by immunizing a Balb/c mouse with HL60 human promyelocytic leukemia cells, was found to react with both HL60 cells and with the K562(S) cell line. This monoclonal antibody binds and immunoprecipitates a glycoprotein (Mr 87,000) present on the cell surface membrane of K562(S) as a disulfide bonded dimer. In competition experiments L5.1 competes with both transferrin and OKT9 (a known antitransferrin receptor antibody) for binding to target K562(S) erythroleukemia cells. Binding of both L5.1 and transferrin to the surface of K562(S) cells is inhibited by treatment with 12--O-tetradecanoyl-phorbol-13-acetate, and the extent and time course of inhibition is similar in both cases. Cell sorting analysis of normal human marrow cells incubated with L5.1 indicates that L5.1 reacts strongly with all the morphologically recognizable erythroid lineage precursors, from the pronormoblast to the orthochromatic normoblast, and with reticulocytes. Erythrocytes, myeloid elements, monocytes, megakaryocytes and platelets, peripheral blood B and T lymphocytes do not bind significantly with this antibody and only a small fraction of promyelocytes was reactive. Antibody L5.1 did not react with leukemic cells of patients with acute lymphoblastic, myeloblastic and promyelocytic leukemias, but it did react with some established B (1 of 5) and T (2 of 3) cell lines, and a myeloid (1 of 3) cell line, and with PHA-stimulated peripheral blood lymphocytes. The nonhemopoietic cell lines tested did not bind with L5.1 with the exception of a colorectal adenocarcinoma and a melanoma cell line, which were both strongly positive. The relationship of antibody L5.1 to other monoclonal antibodies that bind the transferrin receptor is discussed.

Animals↗
PubMed1981

Preleukemia in children.

Six children who developed acute myelomonocytic leukemia presented with a preleukemic syndrome. The incidence of preleukemic presentation of AMML was 17% of children with acute nonlymphocytic leukemia, or 2.9% of all children with acute leukemia at this institution, incidences similar to those in adults. During the preleukemic phase, which lasted from three to 35 months, all children had anemia, all had infectious complications, and three of six had hemorrhagic tendencies. Three received steroids before the diagnosis of AMML, and all had some objective response. Two patients died before receiving therapy for AMML. Four children who received AMML therapy with combinations including cytosine arabinoside and an anthracycline achieved complete remission. Ultimately, all patients died. Clues to diagnosis of preleukemia include unexplained cytopenias, either absolute or functional, peripheral blasts, progressive megaloblastosis with an elevated B12 value, dyserythropoiesis, abnormalities of nuclear segmentation, nonrandom chromosomal alterations, and reduced marrow colony to cluster ratio in vitro. Until there is a highly effective therapy for ANLL, precisely when to treat the child with preleukemia remains uncertain. However, treatment should be started before infectious complications or hemorrhagic tendencies become life-threatening.

Adolescent↗
PubMed1980

Sparing of the brain in neonatal undernutrition: amino acid transport and incorporation into brain and muscle.

Rates of tyrosine and lysine transport and incorporation into protein were measured in control and undernourished weanling rats. Undernutrition was induced by feeding lactating dams a low protein diet (12 percent casein) from birth to day 21. At weaning, body and brain weights of undernourished rats were 50 percent and 88 percent, respectively, of control values. Lysine and tyrosine transport rates into skeletal muscle were reduced by over 75 percent, more than twice the reduction seen in brain. Rates of amino acid incorporation into muscle protein were reduced by approximately 50 percent; the change in rate of incorporation into brain protein was not statistically significant. These data indicate that, in spite of marked retardation of amino acid transport into brain, the brain seems fully capable of maintaining normal rates of protein synthesis.

Amino Acids↗
PubMed1980

Epstein-Barr virus-related serology in marrow transplant recipients.

Serial sera from 50 marrow transplant recipients were examined for their spectra and titers of antibodies to EBV-specific antigens. Immediately before or after transplant, blood products passively transferred antibodies to EB viral capsid antigen (VCA) and EBV nuclear antigen (EBNA). In most recipients, passively-transferred antibodies were replaced by endogenous antibodies regardless of whether donor or recipient had EBV antibodies before transplantation. Commencement or resumption of endogenous EBV antibody production was not associated with signs of infectious mononucleosis or heterophil antibody responses. Antibodies to VCA rose to abnormally high titers, followed successively by antibody to early antigens (EA), and disproportionately low levels of anti-EBNA. Unusually high anti-VCA and anti-EA levels persisted when tests of immune function returned to normal. Antibodies to other herpes group viruses showed no consistent changes. We conclude that (1) EBV does not cause significant clinical problems in marrow transplant recipients; (2) persistent EBV infection can become established or reestablished in the presence of antibodies to EBV; (3) marrow transplant recipients show the same exaggerated immune response to EBV as other immunodeficient patients; and (4) the pattern of EBV-specific antibodies may be a more sensitive measure of defective cell-mediated immunity than most conventional tests of immune function.

Adolescent↗
PubMed1980

Differentiation of human leukemias in response to 12-0-tetradecanoylphorbol-13-acetate in vitro.

Leukemic cells from patients with acute myeloid leukemia underwent morphological, functional, and histochemical changes within 24-48 hr after treatment with 1.6 x 10-18 M 12-0-tetradecanoylphorbol-13-acetate (TPA). The changes included adhesion to the plastic substrate, a 4-6-fold increase in the number of phagocytic cells, and an increase in the number of alpha-naphthyl-acetate esterase (alpha-NAE) positive cells. In contrast, TPA treatment of cells from patients with acute lymphoblastic leukemia caused some aggregation of cells in suspension, but no changes in adhesion, phagocytosis, or alpha-NAE. Of the four cases of undifferentiated or unclassified leukemias studied, two failed to respond to TPA, one responded with a myeloid (adhesion) pattern, and one with a lymphoid (aggregation) pattern. These data suggest that leukemic myeloblasts retain the ability to express a variety of differentiated functions, and in some cases, it may be possible to use TPA as a tool to test the differentiative potential of undifferentiated human leukemias.

Cell Adhesion↗